The reduction of body weight with liraglutide, a once-daily human GLP-I analogue for type 2 diabetes, primarily comes from fat tissue and the fat tissue lost is predominantly visceral fat
Författare
Avdelning/ar
Publiceringsår
2008
Språk
Engelska
Sidor
318-318
Publikation/Tidskrift/Serie
Diabetologia
Volym
51
Issue
S1
Dokumenttyp
Konferensbidrag: abstract
Förlag
Springer
Ämne
- Endocrinology and Diabetes
Conference name
44th EASD Annual Meeting of the European Association for the Study of Diabetes
Conference date
2008-09-08 - 2008-09-11
Conference place
Rome, Italy
Status
Published
ISBN/ISSN/Övrigt
- ISSN: 1432-0428